Plain-English translation of NCT06848894 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called to see if it can help people recover better from acute ischemic stroke when given alongside standard emergency treatments like clot-busting drugs or mechanical removal of clots. Half of the participants will receive the medication, and half will receive a placebo (a dummy injection). Researchers will follow everyone for 90 days to compare how well each group recovers.
Stroke is a serious medical emergency, and while current treatments like clot-busting drugs and mechanical thrombectomy can help, researchers want to know if adding this medication might improve recovery even further and help more patients return to their normal activities.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication or a placebo, both given as daily injections alongside your standard stroke treatment. You'll receive injections for 10 to 14 days depending on how long you stay in the hospital. After that, you'll have follow-up visits and assessments over the next 90 days so doctors can track your recovery and compare your progress to others in the study.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Sponsor
Beijing Tiantan Hospital
Enrollment target
~1,204 participants
Started
March 2025
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wang Yilong, MD, PhD
Beijing Tiantan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.